Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Hank Payments Achieves Record Growth in its Profitable Auto Channel (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Sophiris Bio Inc SPHS

Healthcare Biotechnology
Sophiris Bio Inc is a clinical-stage biopharmaceutical company. It focuses on the development of products for the treatment of urological diseases. The company's product portfolio includes topsalysin (PRX302), for the treatment of lower urinary tract symptoms of benign prostatic hyperplasia (BPH), as well as for the treatment of localized low to intermediate risk prostate cancer. Topsalysin is... see more

Recent & Breaking News (EXPM:SPHS)

Sophiris Bio To Shut Down Operations

PR Newswire May 18, 2020

Sophiris Bio Announces Nasdaq Delisting

GlobeNewswire March 10, 2020

Sophiris Bio Reports Third Quarter 2019 Financial Results and Recent Corporate Highlights

GlobeNewswire November 7, 2019

Sophiris Bio Receives Positive Feedback from FDA Regarding Phase 3 Localized Prostate Cancer Clinical Trial Design

PR Newswire October 21, 2019

Sophiris Bio to Present at the H.C. Wainwright 21st Annual Global Investment Conference

PR Newswire August 30, 2019

Sophiris Bio Announces Completion of $4.0 Million Registered Direct Offering

PR Newswire August 30, 2019

Sophiris Bio Announces $4.0 Million Registered Direct Offering

PR Newswire August 27, 2019

Sophiris Bio Reports Second Quarter 2019 Financial Results and Recent Corporate Highlights

PR Newswire August 9, 2019

Sophiris Bio Receives Positive Feedback from European Medicines Agency Regarding Phase 3 Localized Prostate Cancer Clinical Trial Design

PR Newswire June 19, 2019

Sophiris Bio Reports First Quarter 2019 Financial Results

PR Newswire May 9, 2019

Sophiris Bio Reports Fourth Quarter 2018 and Year-end Financial Results and Recent Corporate Highlights

PR Newswire March 13, 2019

Mid-Afternoon Market Update: Dow Down Over 350 Points; Sophiris Bio Shares Plummet

Benzinga.com  December 17, 2018

Mid-Day Market Update: Crude Oil Down Over 1%; Diffusion Pharmaceuticals Shares Spike Higher

Benzinga.com  December 17, 2018

Mid-Morning Market Update: Markets Open Lower; Hitachi To Acquire ABB's Power-Grid Unit

Benzinga.com  December 17, 2018

Sophiris Bio Provides Updates on Phase 2b Localized Prostate Cancer Trial

PR Newswire December 17, 2018

Report: Exploring Fundamental Drivers Behind HC2, Pangaea Logistics Solutions, Sophiris Bio, Acacia Research, JAKKS Pacific, and LeMaitre Vascular — New Horizons, Emerging Trends, and Upcoming Developments

GlobeNewswire November 16, 2018

Sophiris Bio to Present at the Piper Jaffray Healthcare Conference

PR Newswire November 15, 2018

Sophiris Bio Reports Third Quarter 2018 Financial Results and Recent Corporate Highlights

PR Newswire November 13, 2018

Sophiris Bio to Present at the Cantor Global Healthcare Conference

PR Newswire September 25, 2018

Sophiris Bio Extends the Interest Only Period under its Loan and Security Agreement

PR Newswire September 14, 2018